CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
CPRX on Nasdaq
Shares outstanding
123,180,519
Price per share
$23.34
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
103,326,904
Total reported value
$2,035,690,287
% of total 13F portfolios
0%
Share change
+1,883,526
Value change
+$32,888,064
Number of holders
353
Price from insider filings
$23.34
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% $409,654,062 16,892,951 BlackRock, Inc. 31 Mar 2025
STATE STREET CORP 5.2% $126,186,124 6,405,387 STATE STREET CORPORATION 30 Sep 2025
Flynn James E 2.6% $75,975,517 3,133,011 Deerfield Mgmt, L.P. 31 Dec 2024

As of 30 Sep 2025, 353 institutional investors reported holding 103,326,904 shares of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX). This represents 84% of the company’s total 123,180,519 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 18,216,060 -3.6% 0.01% $358,856,382
VANGUARD GROUP INC 7.1% 8,713,520 -0.6% 0% $171,656,344
STATE STREET CORP 5.2% 6,405,387 +17% 0% $126,186,124
DEERFIELD MANAGEMENT COMPANY, L.P. 4% 4,974,767 +73% 1.5% $98,002,910
RENAISSANCE TECHNOLOGIES LLC 2.9% 3,544,830 +9% 0.09% $69,833,151
Fundsmith LLP 2.7% 3,363,807 +24% 0.33% $66,266,998
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,890,320 +0.82% 0% $56,946,376
AMERICAN CENTURY COMPANIES INC 2.1% 2,528,186 +44% 0.03% $49,805,264
DIMENSIONAL FUND ADVISORS LP 2% 2,458,169 +29% 0.01% $48,424,317
BANK OF AMERICA CORP /DE/ 1.9% 2,291,414 -3.1% 0% $45,140,856
ROYCE & ASSOCIATES LP 1.7% 2,034,965 +29% 0.4% $40,088,810
MORGAN STANLEY 1.5% 1,843,624 -42% 0% $36,319,427
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 1,331,990 -7.3% 0% $26,240,203
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.1% 1,304,774 +6.6% 0.02% $25,704,048
Boston Partners 1% 1,291,059 +0.65% 0.03% $25,576,819
NORTHERN TRUST CORP 1% 1,263,888 -0.88% 0% $24,898,594
Invesco Ltd. 1% 1,233,257 +1.6% 0% $24,295,163
MILLENNIUM MANAGEMENT LLC 0.96% 1,179,182 +174% 0.02% $23,229,885
KENNEDY CAPITAL MANAGEMENT LLC 0.86% 1,060,207 +5% 0.46% $20,886,078
GOLDMAN SACHS GROUP INC 0.82% 1,007,235 -58% 0% $19,842,530
Qube Research & Technologies Ltd 0.67% 821,202 -19% 0.02% $16,177,679
Allianz Asset Management GmbH 0.65% 797,948 -23% 0.02% $15,719,575
Legal & General Group Plc 0.63% 774,104 +17% 0% $15,249,849
RAYMOND JAMES FINANCIAL INC 0.63% 773,330 -8.5% 0% $15,234,600
MACQUARIE GROUP LTD 0.62% 761,740 -16% 0.02% $15,006,000

Institutional Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 550,238 $12,820,145 -$4,515,267 $23.34 18
2025 Q3 103,326,904 $2,035,690,287 +$32,888,064 $19.70 353
2025 Q2 101,339,025 $2,199,165,165 +$74,610,963 $21.70 360
2025 Q1 97,918,497 $2,372,862,063 +$45,703,211 $24.25 364
2024 Q4 97,471,722 $2,035,073,296 +$40,623,932 $20.87 333
2024 Q3 95,275,856 $1,894,559,103 -$37,283,082 $19.88 310
2024 Q2 96,978,257 $1,502,328,440 +$14,034,151 $15.49 268
2024 Q1 96,136,731 $1,532,211,013 +$191,772,043 $15.94 267
2023 Q4 104,057 $1,749,197 +$537,611 $16.81 2
2023 Q3 81,144,515 $948,637,092 -$23,676,606 $11.69 252
2023 Q2 82,204,789 $1,104,755,817 -$95,343,724 $13.44 241
2023 Q1 88,776,605 $1,471,947,983 +$71,018,451 $16.58 255
2022 Q4 84,019,695 $1,562,831,949 -$9,963,436 $18.60 250
2022 Q3 82,060,318 $1,053,130,229 +$184,594,540 $12.83 215
2022 Q2 73,788,241 $515,112,317 +$38,277,838 $7.01 170
2022 Q1 67,694,364 $560,532,235 +$34,540,737 $8.29 176
2021 Q4 65,286,045 $441,726,116 +$3,777,607 $6.77 157
2021 Q3 65,091,816 $344,734,769 -$1,801,558 $5.30 138
2021 Q2 65,333,492 $375,670,274 -$10,223,010 $5.75 136
2021 Q1 67,605,040 $311,553,548 +$11,296,646 $4.61 131
2020 Q4 66,575,924 $222,407,153 -$12,653,106 $3.34 130
2020 Q3 67,876,876 $201,902,589 +$814,375 $2.97 138
2020 Q2 64,700,863 $299,014,386 -$2,996,620 $4.62 136
2020 Q1 63,114,322 $243,054,747 +$12,187,536 $3.85 126
2019 Q4 59,965,370 $224,879,867 -$31,610,750 $3.75 125
2019 Q3 61,530,428 $326,708,529 +$8,441,046 $5.31 114
2019 Q2 61,540,743 $236,207,732 -$4,805,094 $3.84 98
2019 Q1 61,470,723 $313,502,586 +$64,060,074 $5.10 86
2018 Q4 49,060,631 $94,190,873 -$22,033,163 $1.92 83
2018 Q3 50,975,221 $192,678,979 -$11,367,823 $3.78 94
2018 Q2 53,974,837 $168,510,308 +$2,659,913 $3.12 96
2018 Q1 54,698,746 $130,727,787 -$11,122,642 $2.39 96
2017 Q4 56,054,705 $219,181,091 +$80,358,817 $3.91 105
2017 Q3 35,588,895 $89,643,592 +$4,335,637 $2.52 76
2017 Q2 33,945,750 $93,688,694 +$24,746,005 $2.76 67
2017 Q1 25,299,931 $49,329,000 +$4,787,402 $1.95 51
2016 Q4 23,799,664 $24,987,000 +$503,038 $1.05 49
2016 Q3 23,292,967 $25,385,000 -$1,706,152 $1.09 45
2016 Q2 25,350,615 $17,996,000 -$12,323,957 $0.71 56
2016 Q1 36,943,249 $43,220,000 -$15,831,739 $1.17 70
2015 Q4 42,339,667 $103,736,627 -$6,355,335 $2.45 84
2015 Q3 44,724,461 $134,180,687 +$1,578,214 $3.00 88
2015 Q2 43,330,677 $179,273,198 +$18,554,847 $4.13 85
2015 Q1 38,780,695 $167,805,940 +$54,522,050 $4.33 64
2014 Q4 27,154,228 $80,663,000 +$8,338,316 $2.97 48
2014 Q3 23,503,530 $78,031,100 +$8,079,220 $3.32 51
2014 Q2 22,164,659 $56,076,420 +$29,949,473 $2.53 45
2014 Q1 10,334,980 $23,356,120 +$2,871,461 $2.26 35